The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ISLB 2022 | Potential of liquid biopsy in lung cancer
Umberto Malapelle, PhD, University of Naples Federico II, Naples, Italy, discusses current uses of liquid biopsy in clinical practice for patients with lung cancer, and explains the advantages of the complimentary approach of analysing tissue and liquid biopsy simultaneously. This interview took place at the International Society of Liquid Biopsy (ISLB) 2022 congress in Miami, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Speaker’s bureau for Boehringer Ingelheim, AstraZeneca, Roche, MSD, Amgen, Merck, BMS, Thermofisher, Biocartis.
Advisory role for Boehringer Ingelheim, MSD, Amgen, Merck, BMS, Diaceutics, Roche, Eli Lilly, Thermofisher, Janssen.
